Gyre Therapeutics (NASDAQ:GYRE) Trading 4.1% Higher

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price traded up 4.1% during mid-day trading on Wednesday . The stock traded as high as $12.90 and last traded at $12.90. 13,041 shares changed hands during trading, a decline of 82% from the average session volume of 73,098 shares. The stock had previously closed at $12.39.

Gyre Therapeutics Trading Up 0.3 %

The company’s 50 day simple moving average is $12.42 and its 200-day simple moving average is $14.38.

Insider Buying and Selling

In other Gyre Therapeutics news, Director Nassim Usman sold 3,452 shares of the business’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the transaction, the director now directly owns 1,636 shares in the company, valued at approximately $19,632. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.92% of the stock is owned by company insiders.

Institutional Trading of Gyre Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers purchased a new position in shares of Gyre Therapeutics during the 2nd quarter worth about $123,000. Renaissance Technologies LLC acquired a new position in Gyre Therapeutics during the second quarter worth approximately $166,000. Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics during the second quarter worth approximately $218,000. Finally, WINTON GROUP Ltd purchased a new position in Gyre Therapeutics during the second quarter worth approximately $220,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.